Guides
Dose commonly discussed range |
Cycle common use window |
Time Off break between cycles |
Notes context & cautions
01
Research Peptides
| Peptide | Injectable Dose | Topical Dose | Cycle | Time Off | Benefits | Notes | Blood Work | Actions |
|---|---|---|---|---|---|---|---|---|
| FOX04-DR 10mg | 0.25–0.5 mg/day sub-Q | — | 3-day cycles every 4–12 weeks | 4+ weeks | Senescent cell clearance, cellular rejuvenation, longevity | Highly advanced; targets p53 to induce apoptosis in senescent cells; one of the most potent longevity compounds in research | CBC, CMP, inflammatory markers (CRP, IL-6) | |
| Ovagen 20mg | 10–150 mcg/day sub-Q | — | 10-day cycles, 1–2x per year | 3–6 months | Liver tissue support, hepatic function, detoxification suppor | Khavinson bioregulator targeting liver tissue; used in hepatic health and longevity protocols | CMP, CBC, liver enzymes (ALT, AST, GGT) | |
| Prostamax 20mg | 0.5–1 mg/day sub-Q | — | 10-day cycles, 1–2x per year | 3–6 months | Prostate tissue support, male urinary and reproductive health | Khavinson bioregulator targeting prostate tissue; relevant for aging male health protocols | PSA, total testosterone, CMP | |
| Testagen 20mg | 100–300 mcg/day sub-Q | — | 10-day cycles, 1–2x per year | 3–6 months | Testicular tissue support, male hormonal function | Khavinson bioregulator targeting testicular tissue; used in male longevity and hormonal support protocols | Total/free testosterone, LH, FSH, CMP | |
| Vesugen 20mg | 0.5–2 mg/day sub-Q | — | 10-day cycles, 1–2x per year | 3–6 months | Vascular health, cardiovascular tissue support, circulation | Khavinson bioregulator peptide targeting vascular tissue; part of Russian bioregulator series | CMP, CBC, cardiovascular panel, blood pressure | |
| PE-22-28 10mg | Injectable: 50–200 mcg/day sub-Q. Nasal: per product label | — | 2–4 weeks | 1–2 weeks | Antidepressant activity, neuroplasticity, cognitive support | Spadin analog; TREK-1 channel modulator; highly experimental | Baseline CBC, CMP | |
| P21 10mg | Injectable: 100–300 mcg/day sub-Q | — | 2–4 weeks2–4 weeks | 2–4 weeks | Neurogenesis, cognitive enhancement, BDNF modulation | CNTF analog; advanced/experimental; limited human data — research use only | Baseline CBC, CMP | |
| N-Acetyl Selank 10mg | Nasal: 125–250 mcg per nostril 1–2x daily. Injectable: 250–500 mcg/day sub-Q | — | 2–4 weeks | 1–2 weeks | Anxiolytic, stress reduction, mood stabilization without sedation | Acetylated form of Selank — longer-acting profile; often preferred over standard Selan | Baseline CBC, cortisol optional | |
| N-Acetyl Semax 10mg | Nasal: 50–100 mcg per nostril 1–2x daily. Injectable: 200–500 mcg/day sub-Q | — | 2–4 weeks | 1–2 weeks | Enhanced focus, BDNF support, neuroprotection, mood | Acetylated form of Semax — reported longer duration of action than standard Semax | Baseline CBC, CMP | |
| Kisspeptin-10 10mg | 100–200 mcg/day sub-Q | — | 4–8 weeks | 2–4 weeks | Hormonal signaling, LH/FSH support, libido | Used in fertility and hormonal optimization discussions | LH, FSH, total testosterone, estradiol | |
| Oxytocin 10mg | Injectable: 100–500 mcg/day sub-Q. Intranasal: 8 IU per nostril per dose | — | As needed | As needed | Social bonding, mood, intimacy | Intranasal standard; injectable faster onset | Baseline CBC, CMP | |
| Follistatin-344 10mg | 50–100 mcg/day sub-Q or IM near target muscle | — | 10–30 days | 4–6 weeks | Muscle growth, myostatin inhibition | Short cycles common; advanced and experimental | FSH, LH, testosterone, CMP | |
| IGF-1 LR3 1mg | 20–50 mcg/day sub-Q | — | 4–6 weeks | 4 weeks | Muscle growth, recovery, satellite-cell activation | Monitor blood glucose; higher-risk category | IGF-1, fasting glucose, insulin, CMP | |
| GHRP-6 5mg | 100–300 mcg per injection sub-Q | — | 6–12 weeks | 3–4 weeks | GH release, appetite stimulation | Significant hunger side effect; glucose and cortisol concerns | IGF-1, cortisol, fasting glucose, prolactin | |
| GHRP-2 5mg | 100–300 mcg/day sub-Q | — | 6–12 weeks | 3–4 weeks | GH release, recovery, appetite effects | More aggressive GH release; cortisol/prolactin increases possible | IGF-1, cortisol, fasting glucose, prolactin | |
| Sermorelin 5mg | 200–500 mcg/day sub-Q | — | 8–16 weeks | 3–4 weeks | GH secretagogue, sleep, recovery | More recognized in clinical wellness settings | IGF-1, fasting glucose, cortisol | |
| CJC-1295 DAC 5mg | 0.3–1 mg per injection sub-Q | — | 8–12 weeks | 3–4 weeks | Longer-acting GH support | Much lower frequency than no-DAC; do not treat them the same | IGF-1, fasting glucose | |
| SLU-PP-332 5mg | 250 mcg/day sub-Q or per protocol | — | 4–8 weeks | 2–4 weeks | Metabolic support, exercise mimetic interest | Highly experimental; limited human data | — | |
| 5-Amino-1MQ 50mg | 25–50 mg/day oral capsule | — | 4–8 weeks | 2–4 weeks | Energy, body composition, metabolic support | Oral only; not injectable | CMP, fasting glucose, lipid panel | |
| HGH Frag 176-191 10mg | 250–500 mcg/day sub-Q split 2x (fasted AM + pre-bed) | — | 4–12 weeks | 2–4 weeks | Fat metabolism, lipolysis | Best fasted; no appetite stimulation unlike full GH | Fasting glucose, IGF-1, CMP | |
| AOD-9604 5mg | 0.3–0.5 mg/day sub-Q | — | 4–12 weeks | 2–4 weeks | Fat-loss oriented use | Best administered fasted; no topical standard | Fasting glucose, IGF-1, CMP | |
| Cagri + Sema Stack 5mg +5mg | 0.25–2.4 mg/week each sub-Q | — | 8–16+ weeks | 4–6 weeks | Appetite control and fat-loss synergy | Dose refers to each ingredient separately | — | |
| Cagrilintide 5mg | 0.6–4.5 mg/week sub-Q | — | 12–24 weeks | No standard time off | Appetite suppression | Usually stacked with sema in research settings | HbA1c, fasting insulin, CMP, lipid panel | |
| Semaglutide 10mg | 0.25 mg/week → titrate to 0.5 → 1 → 1.7 → 2.4 mg/week sub-Q | — | 12–16+ weeks | No fixed time off | Appetite suppression, weight loss, glycemic support | GI sides common on ramp-up; slow titration reduces nause | Lipase, amylase, HbA1c, fasting insulin, thyroid panel, CMP | |
| AHK-Cu | Injectable: 1–2 mg/day sub-Q | Topical: 1–5% solution 1–2x daily | 4–8 weeks | 2–4 weeks | Hair growth, scalp health, skin quality, collagen support | Copper peptide similar to GHK-Cu; strong focus on hair follicle research | CMP baseline | |
| ARA-290 | 2–4 mg/day sub-Q | No standard topical use | 4–8 weeks | 2–4 weeks | Neuroprotection, pain support, tissue repair, insulin sensitivity | Erythropoietin analog; advanced/experimental; primarily research use | CBC, CMP, HbA1c | |
| Glow | Per blend label; typically 1–2x daily | Per blend label | 4–6 weeks | 2–4 weeks | Skin, healing, cosmetic support | Check ingredient breakdown for active amounts | CMP, CBC | |
| LL37 | 50–400 mcg/day sub-Q | 50–100 mcg per application, 1–2x daily | 2–6 weeks | 2–4 weeks | Antimicrobial and immune support | Advanced/experimental; topical for wound and skin | CBC, CMP, CRP | |
| Thymalin | Injectable: 100 mcg/day sub-Q for 10 days | — | 10-day cycles, 1–2x per year | 3–6 months | Immune system regulation, T-cell support, thymic function | Synthetic dipeptide from thymopoietin; part of Russian bioregulator immune series | CBC with lymphocytes, CRP, IL-6 | |
| Thymosin Alpha | 0.3–0.5 mg/day sub-Q | No standard topical use | 4–12 weeks | 4 weeks | Immune modulation, inflammation support
|
One of the more documented immune peptides
|
CBC with lymphocytes, CRP, IL-6 | |
| BPC 10mg + TB 10 mg | 0.5–1.5 mg/day sub-Q | 500 mcg–1 mg BPC per application if topical blend | 4–6 weeks | 2–4 weeks | Synergistic soft tissue support, inflammation reduction | Verify exact mg per ingredient in your blend | CMP, CBC | |
| Glutathione | Injectable: 100–200 mg/day sub-Q. IV: 400–1,200 mg IV or IM | Nasal/topical: per product label | 4–8 weeks | 2–4 weeks | Antioxidant support, detoxification, skin brightening, immune support
|
Master antioxidant; IV delivers fastest bioavailability; oral poorly absorbed | CMP, CBC | |
| CJC-1295 no DAC 5mg+ Ipa 5mg | 00–300 mcg/day sub-Q | — | 8–12 weeks | 3–4 weeks | GH pulse, sleep, recovery, lean mass | Inject 30–60 min before bed for best GH pulse | — | |
| Pinealon 20mg | Injectable: 1–2 mg/day sub-Q. Nasal: per product label | — | 10-day cycles, 1–2x per year | 3–6 months | Neuroprotection, circadian rhythm support, cognitive longevity | Khavinson bioregulator targeting pineal gland; part of the Russian bioregulator serie | Baseline CBC, CMP | |
| Ipamorelin 5mg | 100–300 mcg/day sub-Q | — | 8–12 weeks | 3–4 weeks | GH pulse, sleep, recovery, lean mass | Clean GH release; minimal cortisol/prolactin spike | IGF-1, fasting glucose | |
| GHK-CU 50mg | 1–2 mg/day sub-Q | 1–5% cream/serum, 1–2x daily | 4–8 weeks | 2–4 weeks | Skin quality, wound support, hair suppor | Topical most common; injectable for anti-aging/wound protocols | CMP, copper/zinc optional | |
| Epithalon 10mg | 5–10 mg/day sub-Q or IV for 10 consecutive days | — | Every 6–12 months | 3–6 months between cycles | Telomere support, longevity, anti-aging | Short burst cycles; popular in longevity circles | CBC, CMP | |
| Tirzepatide 10mg | 2.5–15 mg/week sub-Q | — | 12–16+ weeks | No fixed time off | Weight loss, appetite control, metabolic support | Stronger weight loss data than sema in head-to-head trials | Lipase, amylase, HbA1c, fasting insulin, thyroid panel, CMP, lipid panel | |
| SS-31 10mg | 5–10 mg/day sub-Q | — | 4–8 weeks | 2–4 weeks | Mitochondrial protection, energy, cellular health, anti-aging | Highly regarded in longevity circles; targets mitochondrial inner membrane directly | — | |
| NAD+ 500mg | Injectable: 50–100 mg/day sub-Q. IV: 250–1,000 mg over 2–4 hrs. Oral: 250–500 mg/day | — | 4–12 weeks | 2–4 weeks | Energy, cognition, mitochondrial support | IV fastest onset; sub-Q solid middle ground | CMP, CBC, NAD+ levels (specialty lab) | |
| KPV 10mg | 200–500 mcg/day sub-Q | 0.1–0.5% concentration, 1–2x daily | 4–8 weeks | 2–4 weeks | GI support, inflammation control, skin calming | Oral capsule form also discussed for gut use | CMP, CRP | |
| Tesamorelin 10mg | 1–2 mg/day sub-Q | — | 12+ weeks | Depends on goal | Visceral fat reduction, GH-axis support | FDA-approved dosing exists; don't mix formulation strengths | IGF-1, fasting glucose, lipid panel, CMP | |
| TB500 10mg | 0.5–1 mg/day sub-Q | Not commonly used topically | 4–8 weeks | 2–4 weeks | Recovery, mobility, tissue repair
|
Often stacked with BPC-157
|
CBC, CMP | |
| Semax 11mg | Injectable: 0.3–0.8 mg/day sub-Q. Intranasal: 50–100 mcg per nostril, 1–3x daily | — | 2–4 weeks | 1–2 weeks | Focus, cognition, neuro-support, mood | Intranasal most common route | Baseline CBC, CMP | |
| Selank 11mg | Injectable: 0.3–0.5 mg/day sub-Q. Intranasal: 125–250 mcg per nostril, 1–3x daily | — | 2–4 weeks | 1–2 weeks | Calm focus, anxiety support, mood | Often paired with Semax | Baseline CBC, cortisol optiona | |
| PT 141 10mg | Injectable: 0.5–1.5 mg/day sub-Q. Intranasal: 1–2 mg per dose | — | As needed | needed As needed | Libido and sexual function support | Start at 0.5–1 mg; nausea is common | CBC, CMP, blood pressure baseline | |
| Retatruide | 2–12 mg/week sub-Q | — | 24–48+ weeks | No standard cycling model | Triple agonist; fat loss, metabolic support | Still investigational; GI effects and elevated heart rate noted | Lipase, amylase, HbA1c, fasting insulin, thyroid panel, CMP, lipid panel | |
| MOTS-C 10mg | 200–1000 mcg/day sub-Q | — | 4–8 weeks | 2–4 weeks | Metabolic and mitochondrial support | Also fits under metabolic health section | CMP, fasting glucose, HbA1c, CBC | |
| BPC-157 10mg | 200–600 mcg/day sub-Q | 500 mcg–1 mg per application, 1–2x daily | 4–8 weeks | 2–4 weeks | Gut support, tendon/ligament healing, tissue repair | Topical for surface wounds; injectable near injury preferred | CMP, CBC |
02
Beauty & Vitality
| Peptide | Injectable Dose | Topical Dose | Cycle | Time Off | Benefits | Notes | Blood Work | Actions |
|---|---|---|---|---|---|---|---|---|
| BPC-157 10mg | 200–600 mcg/day sub-Q | 500 mcg–1 mg per application, 1–2x daily | 4–8 weeks | 2–4 weeks | Gut support, tendon/ligament healing, tissue repair | Topical for surface wounds; injectable near injury preferred | CMP, CBC |
03
Cognitive & Daily Wellness
| Peptide | Injectable Dose | Topical Dose | Cycle | Time Off | Benefits | Notes | Blood Work | Actions |
|---|---|---|---|---|---|---|---|---|
| BPC-157 10mg | 200–600 mcg/day sub-Q | 500 mcg–1 mg per application, 1–2x daily | 4–8 weeks | 2–4 weeks | Gut support, tendon/ligament healing, tissue repair | Topical for surface wounds; injectable near injury preferred | CMP, CBC |
04
Longevity & Anti-Aging
| Peptide | Injectable Dose | Topical Dose | Cycle | Time Off | Benefits | Notes | Blood Work | Actions |
|---|---|---|---|---|---|---|---|---|
| BPC-157 10mg | 200–600 mcg/day sub-Q | 500 mcg–1 mg per application, 1–2x daily | 4–8 weeks | 2–4 weeks | Gut support, tendon/ligament healing, tissue repair | Topical for surface wounds; injectable near injury preferred | CMP, CBC |
05
Performance & Recovery
| Peptide | Injectable Dose | Topical Dose | Cycle | Time Off | Benefits | Notes | Blood Work | Actions |
|---|---|---|---|---|---|---|---|---|
| BPC-157 10mg | 200–600 mcg/day sub-Q | 500 mcg–1 mg per application, 1–2x daily | 4–8 weeks | 2–4 weeks | Gut support, tendon/ligament healing, tissue repair | Topical for surface wounds; injectable near injury preferred | CMP, CBC |